22.94
-3.06 (-11.77%)
| 前收盘价格 | 26.00 |
| 成交量 | 40,557,342 |
| 预期市盈率 (P/E Forward) | 67.53 |
| 价格/销量 (P/S) | 2.49 |
| 股市价格/股市净资产 (P/B) | 18.72 |
| 52周波幅 |
| 营业毛利率 | 9.21% |
| 营业利益率 (TTM) | 10.12% |
| 稀释每股收益 (EPS TTM) | 0.680 |
| 季度收入增长率 (YOY) | 110.70% |
| 季度盈利增长率 (YOY) | 344.70% |
| 总债务/股东权益 (D/E MRQ) | 11.54% |
| 流动比率 (MRQ) | 1.59 |
| 营业现金流 (OCF TTM) | 334.34 M |
| 杠杆自由现金流 (LFCF TTM) | 213.45 M |
| 资产报酬率 (ROA TTM) | 10.76% |
| 股东权益报酬率 (ROE TTM) | 36.79% |
AIStockmoo 评分
| 价值 30% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | -2.2 |
| 财务健康 参考 | 3.4 |
| 时机 30% | -2.5 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | -2.5 |
| 市场情绪 20% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 0.0 |
| 内部交易活动 参考 | 0.0 |
| 机构资金流 参考 | NA |
| 市场环境 | ×1.15 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -4.0% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | 4.4 |
| 最终评分 | -0.85 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Hims & Hers Health, Inc. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| HIMS | - | - | - | 18.72 |
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
|
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 11.13% |
| 机构持股比例 | 82.47% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Aug 2026 | CNBC | Hims & Hers CEO says FTC lawsuit misunderstands how the company works |
投资组合